Protalix BioTherapeutics (PLX) Other Non-Current Assets (2010 - 2017)
Protalix BioTherapeutics (PLX) posted quarterly Other Non-Current Assets of $211000.0 for Q3 2017, down 35.47% year-over-year from $327000.0 in Q3 2016, and down 0.94% quarter-over-quarter from $213000.0 in Q2 2017.
Protalix BioTherapeutics (PLX) Other Non-Current Assets (2010 - 2017) Analysis & Trends
Protalix BioTherapeutics' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $211000.0 for Q3 2017.
- In Q3 2017, Other Non-Current Assets fell 35.47% year-over-year to $211000.0; the TTM figure through Sep 2017 stood at $211000.0 (down 35.47% YoY), while the FY2016 annual figure was $327000.0, down 84.23% from the prior year.
- Other Non-Current Assets for Q3 2017 stood at $211000.0, down from $213000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.1 million in Q4 2014, with the low at $205000.0 in Q1 2017.
- The 4-year median for Other Non-Current Assets is $327000.0 (2016), against an average of $1.1 million.
- The sharpest annual moves came in 2016 and 2017: Other Non-Current Assets sank 84.23% in 2016, then sank 34.26% in 2017.
- Protalix BioTherapeutics' Other Non-Current Assets stood at $5.1 million in 2014, then plunged by 59.35% to $2.1 million in 2015, then tumbled by 84.23% to $327000.0 in 2016, then plunged by 35.47% to $211000.0 in 2017.
- Business Quant data shows PLX's Other Non-Current Assets at $211000.0 in Q3 2017, $213000.0 in Q2 2017, and $205000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Protalix BioTherapeutics | 189.57 Mn | 148.91 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 211,000.00 |
| Jun 30, 2017 | 213,000.00 |
| Mar 31, 2017 | 205,000.00 |
| Dec 31, 2016 | 327,000.00 |
| Sep 30, 2016 | 327,000.00 |
| Jun 30, 2016 | 324,000.00 |
| Mar 31, 2016 | 918,000.00 |
| Dec 31, 2015 | 2.07 Mn |
| Dec 31, 2014 | 5.10 Mn |
| Sep 30, 2011 | 2.04 Mn |
| Jun 30, 2011 | 1.75 Mn |
| Dec 31, 2010 | 942,000.00 |